Drug profile · INN
cadonilimab
cadonilimab is a cytotoxic t-lymphocyte protein 4 inhibitor.
NMPA: clinical trials
Patents linked 0
Pipeline programs 10
News articles 1
Drug details — cadonilimab
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 10
- Data quality
- 0.70
Quick answer
cadonilimab is a cytotoxic t-lymphocyte protein 4 inhibitor.
Key facts
INN cadonilimab
Mechanism Cytotoxic T-lymphocyte protein 4 inhibitor
Target Cytotoxic T-lymphocyte protein 4
Mechanism of action
Cytotoxic T-lymphocyte protein 4 inhibitor
Primary target: Cytotoxic T-lymphocyte protein 4
Approval history
| Authority | Status | Date |
|---|---|---|
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cadonilimab?
cadonilimab is a cytotoxic t-lymphocyte protein 4 inhibitor.